Overcoming immunosuppressive mechanisms.
Widén
K
K
Department of Oncology, Immune and Gene Therapy Laboratory, Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden.
Mozaffari
F
F
Choudhury
A
A
Mellstedt
H
H
D015703:Antigens, CD / Q000276:immunology; D060908:CTLA-4 Antigen; D004167:Diphtheria Toxin / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000627:therapeutic use; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
D015703:Antigens, CD; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D004167:Diphtheria Toxin; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox